ArticleJournal of cosmetic dermatology2025
A Scoping Review of Pathogenesis, Current Treatments, and Novel Approaches for Vitiligo.
Article in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From Mechanisms to Clinical Practice: Advances in Vitiligo Treatment Across Western Medicine and Traditional Chinese Medicine.Clinical, cosmetic and investigational dermatology · 2026Review
- A Scoping Review of Pathogenesis, Current Treatments, and Novel Approaches for Vitiligo.Journal of cosmetic dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundVitiligo is a chronic skin disorder characterized by loss of melanocytes, causing depigmentation and psychological distress. Its pathogenesis is complex and multifactorial, involving genetic predisposition, autoimmune, oxidative stress, and neurogenic mechanisms.
aimsThis scoping review summarizes current understanding of vitiligo pathogenesis and provides an overview of available and emerging treatment modalities.
methodsA systematic search was conducted in Web of Science, Scopus, and EBSCO Medline for English-language publications from January 2019 onwards. Eligible studies included those investigating the pathogenesis, therapeutic approaches, or novel strategies for idiopathic vitiligo across all age groups and clinical types. Exclusion criteria included secondary vitiligo due to drugs, comorbidities, or systemic diseases, as well as studies involving pregnant or lactating women and those reporting negative findings.
resultsThe search identified 5298 relevant articles. Established therapies include topical and oral agents, phototherapy, surgical interventions, and combination regimens. Recent advances highlight novel therapeutic targets and experimental interventions, many of which are not yet approved but show promising preliminary outcomes. These include immune-modulating agents, antioxidants, and regenerative strategies aimed at restoring melanocyte function and repigmentation.
conclusionsVitiligo remains a challenging dermatological disorder with significant clinical and psychosocial implications. Although existing therapies provide variable outcomes, emerging treatments offer encouraging prospects. This review provides a comprehensive resource for clinicians and researchers, guiding future directions in vitiligo management and therapeutic innovation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.